Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience

Méndez-Sánchez, Nahúm; Díaz-Orozco, Luis E.; Córdova-Gallardo, Jacqueline

doi:10.1016/j.jhep.2021.04.021

Cited by 38 publications

(31 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 In addition, feedback from representatives of patient advocacy groups, primary care physicians and nonhepatologists does not suggest that the name change would negatively impact disease awareness. 10,[18][19][20] Currently, the European and American liver associations are organizing a platform to discuss this issue.…”

Section: Mafld Vs Nonalcoholic Fatty Liver Disease (Nafld)mentioning

confidence: 99%

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease

Lin¹,

Zhang²,

Li³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease and affects at least a quarter of the global adult population. It has rapidly become one of the leading causes of hepatocellular carcinoma and cirrhosis in Western countries. In this review, we discuss the nomenclature and definition of MAFLD as well as its prevalence and incidence in different geographical regions. Although cardiovascular disease remains the leading cause of death in MAFLD patients, the proportion of patients dying from hepatic complications increases sharply as the disease progresses to advanced liver fibrosis and cirrhosis. In addition, patients with MAFLD are at increased risk of various extrahepatic cancers. Although a causal relationship between MAFLD and extrahepatic cancers has not been established, clinicians should recognize the association and consider cancer screening (e.g., for colorectal cancer) as appropriate.

show abstract

Section: Mafld Vs Nonalcoholic Fatty Liver Disease (Nafld)mentioning

confidence: 99%

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease

Lin¹,

Zhang²,

Li³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

show abstract

“…Despite new MAFLD positive diagnostic criteria in adults aimed to raise disease’s awareness among Mexican physicians and specialists [ 60 ], the impact of nomenclature for MAFLD in children and adolescents has not been explored. Recently, an international panel of experts proposed MAFLD diagnostic criteria for pediatric patients [ 61 ].…”

Section: Diagnosis Of Mafld In Children and Adolescentsmentioning

confidence: 99%

A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health

et al. 2021

Self Cite

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) affects almost a quarter of the world’s population and is the most common cause of chronic liver disease in children and adolescents. The recent proposal to replace the terminology of NAFLD with metabolic-associated fatty liver disease (MAFLD) aims to reflect the pathophysiology and risk factors for this disease. Importantly, the risk factors for MAFLD may be prenatal, such as genetic factors, or postnatal, such as obesity and insulin resistance. MAFLD is increasingly recognized in children and adolescents. Early diagnosis and identification of high-risk individuals with type 2 diabetes mellitus and metabolic syndrome is important. The diagnosis and management of MAFLD in children and adolescents should follow international clinical guidelines, such as those from the American Diabetes Association (ADA) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Current guidelines recommend lifestyle and dietary modifications, exercise, screening, individualized patient assessment, and multidisciplinary patient management. This review assesses the revised terminology and discusses the epidemiology, risk factors, pathophysiology, diagnosis, and prevention of MAFLD in children and adolescents worldwide and in Mexico, and also considers the implications for public health.

show abstract

“…MAFLD is diagnosed on clinical criteria that are routinely evaluated in high-prevalence populations [ 11 . 12 ]. In contrast, the diagnosis of NAFLD has been a diagnosis of exclusion, which has the disadvantages of challenging diagnostic services and reducing disease awareness [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, the diagnosis of NAFLD has been a diagnosis of exclusion, which has the disadvantages of challenging diagnostic services and reducing disease awareness [ 12 ]. In Mexico, the lack of awareness of MAFLD by physicians has been associated with misdiagnosis and inappropriate treatment and has underestimated the serious consequences of this disease [ 12 ]. There has been a high level of acceptance of the new name among patients [ 13 ], primary care physicians [ 14 ], nurses, and allied health professionals [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Méndez-Sánchez

Díaz-Orozco

2021

Med Sci Monit

Self Cite

View full text Add to dashboard Cite

In 2020, international consensus guidelines recommended the renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), supported by diagnostic criteria. MAFLD affects up to 25% of the global population. However, the rates of MAFLD are likely to be underestimated due to the increasing prevalence of type 2 diabetes mellitus (T2DM) and obesity. Within the next decade, MAFLD has been projected to become a major cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, as well as the most common indication for liver transplantation in the US. This transition in terminology and clinical criteria may increase momentum and clinical evidence at multiple levels, including patient diagnosis, management, and care, and provide the basis for new research areas and clinical development for therapeutics. The diagnostic criteria for MAFLD are practical, simple, and superior to the existing NAFLD criteria for identifying patients at increased risk of developing progressive liver disease. This Editorial aims to present the historical evolution of the terminology for fatty liver disease and the advantages of diagnosis, patient management, and future research on MAFLD.

show abstract

Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience

Cited by 38 publications

References 10 publications

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease

A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Contact Info

Product

Resources

About